TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00977184

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 50 HZ Repetitive TMS

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Study: NCT03057327

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Improve awareness of checking moles
Description: Intervention:~1. Improve awareness Each of the eight changing rooms will have a large mirror that can be used to see the face and chest. Each room will be equipped with a poster, brochures and the SSE kit consisting of the laminated card with a ruler on one edge and the magnifying lens will be fastened to the wall on a cord.~2. Provide education The subject may chose to read the poster and a brochure. c) A woman research assistant will perform in-person exit interviews with participants to ascertain if women noticed the poster, and found the information relevant.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparator
Description: Prior to placing the intervention materials into the changing rooms, 100 eligible subjects will be asked if they regularly check their moles for concerning features. If the response is yes, then they will be asked if they have found concerning moles and what they did next.
Study: NCT00355550

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tricaprilin
Description: Powder formulation will be mixed in a liquid (approximately 8 oz).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powder formulation will be mixed in a liquid (approximately 8 oz).
Study: NCT05669066

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful meditation
Description: Adding mindful meditation to pre- and post-operative care for patients who are having a TKA
Study: NCT02538627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trametinib
Description: trametininb
Study: NCT02726269

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CLA (Clarithro+Lanso+Amoxi)
Description: Tablets of oral administration administered to subjects randomized to this group twice daily for 10 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLA (Panto+Levoflox+Azithro)
Description: Tablets of oral administration to subjects randomized to this group once daily for 10 days.
Study: NCT00496327

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varicella Virus Vaccine Live (Oka-Merck)
Description: VARIVAX(TM) (Refrigerated) \[Varicella Virus Vaccine Live (Oka/Merck), Refrigerator-Stable Formulation.\] Subjects enrolled in the study received one 0.5 mL subcutaneous dose of VARIVAX(TM). Frequency is single dose.
Study: NCT00801268

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tripterygium wilfordii
Description: TW，60mg/d

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Emodin
Description: 100mg/d
Study: NCT01192360

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phase contrast flow velocity mapping (PC)
Description: An MRI is done using the phase contrast flow velocity mapping (PC)technique. Using PC, an imaging slice is prescribed perpendicular to the vessel's course. Within the pulmonary circulation, PC can quantify total pulmonary blood flow and the right / left distribution of the lung blood flow volume.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Phase contrast flow velocity mapping (PC)
Description: An MRI is done using the phase contrast flow velocity mapping (PC)technique. Using PC, an imaging slice is prescribed perpendicular to the vessel's course. Within the pulmonary circulation, PC can quantify total pulmonary blood flow and the right / left distribution of the lung blood flow volume.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced magnetic resonance imaging
Description: Dynamic contrast-enhanced magnetic resonance (DCE MR) perfusion imaging imaging is a non-invasive method to quantify regional pulmonary blood flow. A bolus of gadolinium-containing contrast medium is injected and its passage through the pulmonary circulation traced using a repetitive rapid three-dimensional (3D) T1 weighted angiography sequence.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic contrast-enhanced magnetic resonance imaging
Description: Dynamic contrast-enhanced magnetic resonance (DCE MR) perfusion imaging imaging is a non-invasive method to quantify regional pulmonary blood flow. A bolus of gadolinium-containing contrast medium is injected and its passage through the pulmonary circulation traced using a repetitive rapid three-dimensional (3D) T1 weighted angiography sequence.
Study: NCT03274349

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: whole body electromyostimulation exercise
Description: whole body electromyostimulation exercise training twice a week for 20 min each, bipolar, 85 Hz, intermittent pulse/pause, pulse width 350 µsec

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: protein-rich nutrition therapy
Description: protein-rich nutrition therapy with an objective of reaching 1,2 to 1,5 g protein/kg body weight and day

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: protein-rich nutrition therapy
Description: protein-rich nutrition therapy with an objective of reaching 1,2 to 1,5 g protein/kg body weight and day
Study: NCT01521364

Intervention type: DRUG
Group type: OTHER
Intervention: Addition of different doses of clarithromycin.
Description: At week 1, 250mg clarithromycin once a day will be added to linezolid therapy during two weeks.~At week 3, 500mg clarithromycin once a day will be added to linezolid therapy during to weeks.
Study: NCT02175758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: SOF administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: SOF administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: SOF administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: SOF administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: SOF administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: SOF administered orally once daily
Study: NCT01497587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: Single dose, 0.5 U/kg, administered s.c. (under the skin)
Study: NCT03763435

Intervention type: BEHAVIORAL
Intervention: Antenatal pregnancy classes
Description: At least three comprehensive full-day educational program covering all the stages of pregnancy.
Study: NCT00672984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: immediate release guanfacine hydrochloride
Description: Subjects will receive 2x2mg immediate-release guanfacine on day 1. Subjects will receive 4x2mg immediate-release guanfacine on day 6.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: Subjects will receive 400mg of moxifloxacin on day 1. Subjects will receive 400mg of moxifloxacin on day 6.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo on Day 1. Subjects will receive placebo on Day 6.
Study: NCT00746421

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine XR
Description: oral doses, 200 mg, 300 mg, 400 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 200mg, 300mg or 400mg
Study: NCT00787553

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefazolin
Description: 2.0 g, IV, 2 hours before surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tinidazole
Description: 2.0 g orally, 12 hours before surgery
Study: NCT02175758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV oral solution or capsules will be administered orally in a divided daily dose based on weight
Study: NCT00787553

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefazolin plus tinidazole
Description: cefazolin, 2.0 g IV 2 hours before surgery plus tinidazole 2.0 g orally 12 hours before surgery
Study: NCT02380976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination drug: DW330SR, DW1030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination drug: DW330SR, DW1030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW340
Study: NCT04373083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Administered in 3-week intervals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Administered in 3-week intervals

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved-site radiotherapy (IS-RT)
Description: Patients will receive IS-RT with a dose of 20 Gy. Involved-site radiotherapy will be carried out on the basis of 3D imaging as described in the protocol
Study: NCT02175758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV oral solution or capsules will be administered orally in a divided daily dose based on weight

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: RBV oral solution or capsules will be administered orally in a divided daily dose based on weight
Study: NCT04373083

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Involved-site radiotherapy (IS-RT)
Description: Patients will receive IS-RT with a dose of 20 Gy. Involved-site radiotherapy will be carried out on the basis of 3D imaging as described in the protocol
Study: NCT01137435

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ADACEL™:Adsorbed Diphtheria, Tetanus Toxoids and Component Pertussis Combined
Description: 0.5 mL, intramuscular (IM)
Study: NCT04220892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg intravenous (IV) every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg intravenous (IV) every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 900 mg/m\^2 IV every 3 weeks. Supportive medications of ibuprofen, folic acid, vitamin B12, and dexamethasone.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: 150 mg twice a day, by mouth.
Study: NCT00121225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Patients will receive vorinostat by mouth once a day for 4 weeks. Treatment may repeat every 4 weeks for as long as benefit is shown. Patients will be evaluated for 4 weeks and every 3 months thereafter.
Study: NCT01121406

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Patients receive paclitaxel in a 4 week schedule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Patients receive gemcitabine in a 3 week schedule
Study: NCT01266928

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamine C and E
Description: Eligible and consenting women were randomly assigned to capsules containing a combination of 1,000 mg vitamin C (ascorbic acid) and 400 international units of vitamin E (RRR alpha tocopherol acetate)
Study: NCT03686111

Intervention type: DIAGNOSTIC_TEST
Intervention: oocytes collect
Description: After stimulation, an echo-guided oocyte puncture is performed under anesthesia

Intervention type: DIAGNOSTIC_TEST
Intervention: oocytes collect
Description: After stimulation, an echo-guided oocyte puncture is performed under anesthesia
Study: NCT03418675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rexulti
Description: Atypical antipsychotic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pill that contains no medicine
Study: NCT04162314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Beta-1,3/1,6-D-Glucan Ganoderma lucidum
Description: Beta-1,3/1,6-D-Glucan capsule three times daily for 90 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebos
Study: NCT01845415

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Marketing Campaign
Description: The campaign will involve distribution of posters throughout the communities promoting awareness of the consequences of fall injuries and encouraging people to go to an website that provides safety information and injury stories.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Social Marketing Campaign
Description: The campaign will involve distribution of posters throughout the communities promoting awareness of the consequences of fall injuries and encouraging people to go to an website that provides safety information and injury stories.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention components
Description: Doctors and nurses in these communities will perform health education to parents of 1 through 4 year olds around the risks of falls in the home when these parents visit the doctor for regular visits. Also, several parenting classes in these communities will be modified to include educational videos and discussion of these issues
Study: NCT04822909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast;Apremilast;Apremilast 10 MG; 20 MG; 30 MG Oral Tablet
Description: The study patients will be treated with oral apremilast, administered initially a dose of 10 mg once daily, gradually increasing to reach the maximal therapeutic dosage of 30 mg twice daily before end of 1st week of starting the therapy.~The treatment will be continued till 6 months and we will taper the steroids by 10mg/ 2 weeks till 20mg and then 5 mg/ 2 weeks till discontinuation of steroids.~If a patient worsens after treatment or develops any serious adverse event after initiation of treatment, he will be withdrawn from the study.~If there is no response to the treatment and we are unable to taper steroids after 12 weeks of therapy then the patient will be withdrawn from the study
Study: NCT02455089

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GADD34 RNA level measurement.
Description: Blood analysis including GADD34 RNA level measurement is performed every 3 months up to 1 year for SLE patients.~A modal including physical exam, standard biological results and GADD34 RNA level is correlated to a SLE flare occurence in the next 3 months.
Study: NCT02493855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ombitasvir/ABT-450/Ritonavir
Description: Ombitasvir/ABT-450/ritonavir combination tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ombitasvir/ABT-450/Ritonavir
Description: Ombitasvir/ABT-450/ritonavir combination tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ombitasvir/ABT-450/Ritonavir
Description: Ombitasvir/ABT-450/ritonavir combination tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasabuvir
Description: Dasabuvir tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasabuvir
Description: Dasabuvir tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasabuvir
Description: Dasabuvir tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin tablets
Study: NCT04097912

Intervention type: DRUG
Intervention: Acetylsalicylic Acid (Aspirin, BAYE4465)
Description: 75-100mg
Study: NCT02346916

Intervention type: DRUG
Group type: OTHER
Intervention: Capsaicin
Description: 1 inch ribbon of Capzasin-HP 0.1% will be applied to the forearm for 30 minutes
Study: NCT00864513

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: pemetrexed 500 mg/m2 IV day 1 of each 21 day cycle until disease progression or unacceptable toxicity for a maximum of 8 cycles
Study: NCT03160807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Levolet 500 mg OD for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: Levolet 500 OD for 10 days
Study: NCT01121406

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Patients receive topotecan in 3 or 4 week schedule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD)
Description: Patients receive PLD in a 4 week schedule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 6727
Description: Patients receive BI 6727 infusion every 3 weeks
Study: NCT03078361

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immunochemical Fecal Occult Blood Test (I-FOBT) Kit
Description: Both intervention groups will receive an I-FOBT kit (by study coordinator) with verbal and written instructions in Spanish on how to complete the stool sampling at home within 1 week, and mail the completed kit in the pre-addressed, postage paid mailer. Patients with abnormal results will receive a call explaining the meaning of an abnormal I-FOBT and encouraging them to take specific next steps.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Immunochemical Fecal Occult Blood Test (I-FOBT) Kit
Description: Both intervention groups will receive an I-FOBT kit (by study coordinator) with verbal and written instructions in Spanish on how to complete the stool sampling at home within 1 week, and mail the completed kit in the pre-addressed, postage paid mailer. Patients with abnormal results will receive a call explaining the meaning of an abnormal I-FOBT and encouraging them to take specific next steps.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LATINOS CARES Toolkit
Description: DVD + photonovella booklet), about colorectal cancer screening (CRCS) targeted for a Latino medically underserved population.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Intervention
Description: Standard intervention (CDC brochure) on colorectal cancer screening in community health clinics.
Study: NCT02449564

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sirolimus
Description: sirolimus 1mg daily
Study: NCT03900676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB-1953 - 2%
Description: Topical Gel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB-1953 - 2%
Description: Topical Gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VB-1953 - 0% (Vehicle)
Description: Topical Gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VB-1953 - 0% (Vehicle)
Description: Topical Gel
Study: NCT02514057

Intervention type: OTHER
Intervention: Questionnaire
Description: Form filling only
Study: NCT04776941

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT02514057

Intervention type: OTHER
Intervention: Questionnaire
Description: Form filling only

Intervention type: OTHER
Intervention: Questionnaire
Description: Form filling only
Study: NCT02850198

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: scalp electroacupuncture

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham scalp electroacupuncture
Study: NCT00466752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib tosylate
Description: Given PO

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Description: Correlative studies
Study: NCT04776941

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT04416685

Intervention type: PROCEDURE
Group type: OTHER
Intervention: primary repair
Description: For Level I-II tumors, in case of segmental resection of PV/SMV, the reconstruction was performed by an end-to-end anastomosis either by direct suture (for defect under 2 cm) or by using an interposition venous or prosthetic graft. For this purpose, autologous grafting we used internal jugular vein and cadaveric iliac vein and alternatively, synthetic PTFE graft was also used.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: primary repair
Description: For Level I-II tumors, in case of segmental resection of PV/SMV, the reconstruction was performed by an end-to-end anastomosis either by direct suture (for defect under 2 cm) or by using an interposition venous or prosthetic graft. For this purpose, autologous grafting we used internal jugular vein and cadaveric iliac vein and alternatively, synthetic PTFE graft was also used.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: segmental resection
Description: For Level I-II tumors, in case of segmental resection of PV/SMV, the reconstruction was performed by an end-to-end anastomosis either by direct suture (for defect under 2 cm) or by using an interposition venous or prosthetic graft. For this purpose, autologous grafting we used internal jugular vein and cadaveric iliac vein and alternatively, synthetic PTFE graft was also used.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: segmental resection
Description: For Level I-II tumors, in case of segmental resection of PV/SMV, the reconstruction was performed by an end-to-end anastomosis either by direct suture (for defect under 2 cm) or by using an interposition venous or prosthetic graft. For this purpose, autologous grafting we used internal jugular vein and cadaveric iliac vein and alternatively, synthetic PTFE graft was also used.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: segmental resection
Description: For Level I-II tumors, in case of segmental resection of PV/SMV, the reconstruction was performed by an end-to-end anastomosis either by direct suture (for defect under 2 cm) or by using an interposition venous or prosthetic graft. For this purpose, autologous grafting we used internal jugular vein and cadaveric iliac vein and alternatively, synthetic PTFE graft was also used.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: graft reconstruction
Description: Regarding Level III tumors, complete resection of the tumor was done either by tangential excision or by partial venous excision and subsequent reconstruction. To maintain a secure anastomosis, the mesenteric root was mobilized completely or/and splenic vein was divided.
Study: NCT03548415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS-GHR-LRx
Description: IONIS GHR-LRx administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS-GHR-LRx
Description: IONIS GHR-LRx administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS-GHR-LRx
Description: IONIS GHR-LRx administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IONIS-GHR-LRx
Description: IONIS GHR-LRx administered subcutaneously.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered subcutaneously.
Study: NCT03962816

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 20 µg recombinant hepatitis B vaccine at months 0, 1, and 6
Description: three-dose, 20 µg per dose